These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24811015)

  • 1. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
    Sokol KC; Ghazi A; Kelly BC; Grant JA
    J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mastocytosis and insect venom allergy.
    Bonadonna P; Zanotti R; Müller U
    Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):347-53. PubMed ID: 20485157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.
    da Silva EN; Randall KL
    J Allergy Clin Immunol Pract; 2013; 1(6):687-8. PubMed ID: 24565720
    [No Abstract]   [Full Text] [Related]  

  • 4. Unpredicted adverse reaction to omalizumab.
    Jandus P; Hausmann O; Haeberli G; Gentinetta T; Mueller U; Helbling A
    J Investig Allergol Clin Immunol; 2011; 21(7):563-6. PubMed ID: 22312942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting.
    Palgan K; Bartuzi Z; Gotz-Zbikowska M
    Int J Immunopathol Pharmacol; 2014; 27(1):109-12. PubMed ID: 24674685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy.
    Paraskevopoulos G; Sifnaios E; Christodoulopoulos K; Mantopoulou F; Papakonstantis M; Sabaziotis D
    Eur Ann Allergy Clin Immunol; 2013 Apr; 45(2):52-5. PubMed ID: 23821833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab and hypersensitivity reactions.
    Shankar T; Petrov AA
    Curr Opin Allergy Clin Immunol; 2013 Feb; 13(1):19-24. PubMed ID: 23242113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential treatments for food allergy.
    Albin S; Nowak-Węgrzyn A
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):77-100. PubMed ID: 25459578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab.
    Galera C; Soohun N; Zankar N; Caimmi S; Gallen C; Demoly P
    J Investig Allergol Clin Immunol; 2009; 19(3):225-9. PubMed ID: 19610266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mastocytosis and Hymenoptera venom allergy.
    Ruëff F; Placzek M; Przybilla B
    Curr Opin Allergy Clin Immunol; 2006 Aug; 6(4):284-8. PubMed ID: 16825870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.
    Matito A; Blázquez-Goñi C; Morgado JM; Alvarez-Twose I; Mollejo M; Sánchez-Muñoz L; Escribano L
    Ann Allergy Asthma Immunol; 2013 Nov; 111(5):425-6. PubMed ID: 24125156
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy.
    Nadeau KC; Kohli A; Iyengar S; DeKruyff RH; Umetsu DT
    Immunol Allergy Clin North Am; 2012 Feb; 32(1):111-33. PubMed ID: 22244236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IgE--emerging opportunities for Omalizumab.
    Babu KS; Polosa R; Morjaria JB
    Expert Opin Biol Ther; 2013 May; 13(5):765-77. PubMed ID: 23517576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
    Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
    Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunotherapy in food allergy: towards new strategies.
    Sato S; Yanagida N; Ogura K; Asaumi T; Okada Y; Koike Y; Iikura K; Syukuya A; Ebisawa M
    Asian Pac J Allergy Immunol; 2014 Sep; 32(3):195-202. PubMed ID: 25268336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.
    Mauro M; Incorvaia C; Formigoni C; Elia R; Russello M; Pellegrino D
    Panminerva Med; 2012 Dec; 54(4):305-12. PubMed ID: 23123583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab in chronic urticaria: a retrospective series of 15 cases.
    Armengot-Carbo M; Velasco-Pastor M; Rodrigo-Nicolas B; Pont-Sanjuan V; Quecedo-Estebanez E; Gimeno-Carpio E
    Dermatol Ther; 2013; 26(3):257-9. PubMed ID: 23742285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hymenoptera venom allergy.
    Przybilla B; Ruëff F
    J Dtsch Dermatol Ges; 2010 Feb; 8(2):114-27; quiz 128-30. PubMed ID: 19751222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extraordinary response to omalizumab in a child with severe chronic urticaria.
    Asero R; Casalone R; Iemoli E
    Eur Ann Allergy Clin Immunol; 2014 Jan; 46(1):41-2. PubMed ID: 24702874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific immunotherapy and biological treatments for occupational allergy.
    Moscato G; Pala G; Sastre J
    Curr Opin Allergy Clin Immunol; 2014 Dec; 14(6):576-81. PubMed ID: 25115685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.